Novel derivatives of spiroimidazolidinedione were synthesized and evaluated as hypoglycemic agents through binding to sulfonylurea receptor 1 (SUR1) in pancreatic beta-cells. Their selectivity index was calculated against both aldehyde reductase (ALR1) and aldose reductase (ALR2). Aldehyde reductase is a key enzyme in the polyol pathway that is involved in the etiology of the secondary diabetic complications. All structures were confirmed by microanalysis and by IR, ¹H NMR, ¹³C NMR and EI-MS spectroscopy. The investigated compounds were subjected to molecular docking and an in silico prediction study to determine their free energy of binding (ΔG) values and predict their physicochemical properties and drug-likeness scores. Compound 1′-(5-chlorothiophene-2-ylsulfonyl)spiro[cyclohexane-1,5′-imidazolidine]-2′,4′-dione showed IC₅₀ 0.47 µM and 79% reduction in blood glucose level with a selectivity index 127 for ALR2.

合成了螺氨基咪唑烷二酮的新型衍生物，并通过与胰腺β细胞中的磺酰脲受体1（SUR1）结合作为降血糖药进行了评估。计算了针对醛还原酶（ALR1）和醛糖还原酶（ALR2）的选择性指数。醛还原酶是多元醇途径中的关键酶，参与继发性糖尿病并发症的病因学。通过微分析以及通过IR，¹ H NMR，¹³ C NMR和EI-MS光谱确认所有结构。研究的化合物进行了分子对接和计算机模拟预测研究，以确定其结合自由能（ΔG）值，并预测其理化性质和药物相似性得分。化合物1'-（5-氯噻吩-2-基磺酰基）螺[环己烷-1,5'-咪唑烷] -2'，4'-二酮的IC _50为0.47 µM，血糖水平降低79％，选择性指数为127适用于ALR2。